The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.
After the EPIS FWD notification of a cluster of hepatitis A cases infected with two distinct strains in several EU/EEA countries, this risk assessment presents the early findings of this multi-country hepatitis A outbreak and sets out initial options for response.
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
The key objective of this meeting was to verify the rationale and objectives of molecular typing for surveillance of hepatitis E virus (HEV) through the hepatitis E network (HEVnet). The workshop reviewed HEVnet as a tool for molecular surveillance of HEV in Europe.